A Randomized Trial of a Low-Trapping Nonselective N-Methyl-D-Aspartate Channel Blocker in Major Depression

[1]  Dennis S. Charney,et al.  Ketamine for Depression: Where Do We Go from Here? , 2012, Biological Psychiatry.

[2]  G. Laje,et al.  Relationship of Ketamine's Plasma Metabolites with Response, Diagnosis, and Side Effects in Major Depression , 2012, Biological Psychiatry.

[3]  D. Luckenbaugh,et al.  A Randomized, Placebo-Controlled, Crossover Pilot Trial of the Oral Selective NR2B Antagonist MK-0657 in Patients With Treatment-Resistant Major Depressive Disorder , 2012, Journal of clinical psychopharmacology.

[4]  D. Luckenbaugh,et al.  Replication of Ketamine's Antidepressant Efficacy in Bipolar Depression: A Randomized Controlled Add-On Trial , 2012, Biological Psychiatry.

[5]  D. Luckenbaugh,et al.  Rapid antidepressant changes with sleep deprivation in major depressive disorder are associated with changes in vascular endothelial growth factor (VEGF): A pilot study , 2011, Brain Research Bulletin.

[6]  E. Kavalali,et al.  NMDA Receptor Blockade at Rest Triggers Rapid Behavioural Antidepressant Responses , 2011, Nature.

[7]  J. Krystal,et al.  The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [1H]-MRS , 2011, Psychiatry Research: Neuroimaging.

[8]  L. Harrington,et al.  Glycogen Synthase Kinase-3 Is an Early Determinant in the Differentiation of Pathogenic Th17 Cells , 2011, The Journal of Immunology.

[9]  Nanxin Li,et al.  mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists , 2010, Science.

[10]  D. Luckenbaugh,et al.  A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. , 2010, Archives of general psychiatry.

[11]  D. Charney,et al.  Safety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression , 2010, Biological Psychiatry.

[12]  M. Kano,et al.  Involvement of NMDAR2A tyrosine phosphorylation in depression‐related behaviour , 2009, The EMBO journal.

[13]  P. Skolnick,et al.  Glutamate-based antidepressants: 20 years on. , 2009, Trends in pharmacological sciences.

[14]  C. Stockmeier,et al.  Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression , 2009, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[15]  A. Placentino,et al.  VEGF serum levels in depressed patients during SSRI antidepressant treatment , 2009, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[16]  T. Insel,et al.  The STAR*D trial: revealing the need for better treatments. , 2009, Psychiatric services.

[17]  M. Krams,et al.  An Innovative Design to Establish Proof of Concept of the Antidepressant Effects of the NR2B Subunit Selective N-Methyl-D-Aspartate Antagonist, CP-101,606, in Patients With Treatment-Refractory Major Depressive Disorder , 2008, Journal of clinical psychopharmacology.

[18]  D. Luckenbaugh,et al.  Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. , 2008, The Journal of clinical psychiatry.

[19]  I. Heuser,et al.  Serum Concentrations of Nerve Growth Factor and Brain-Derived Neurotrophic Factor in Depressed Patients before and after Antidepressant Treatment , 2008, Pharmacopsychiatry.

[20]  Guang Chen,et al.  Cellular Mechanisms Underlying the Antidepressant Effects of Ketamine: Role of α-Amino-3-Hydroxy-5-Methylisoxazole-4-Propionic Acid Receptors , 2008, Biological Psychiatry.

[21]  Hongwei Song,et al.  Gene expression and association analysis of vascular endothelial growth factor in major depressive disorder , 2007, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[22]  Paul J Carlson,et al.  A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. , 2006, Archives of general psychiatry.

[23]  J. Witkin,et al.  Sensitive and rapid behavioral differentiation ofN-methyl-d-aspartate receptor antagonists , 1994, Psychopharmacology.

[24]  M. First,et al.  Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research version (SCID-I RV) , 2002 .

[25]  K. Lees,et al.  Tolerability of the Low-Affinity, Use-Dependent NMDA Antagonist AR-R15896AR in Stroke Patients: A Dose-Ranging Study , 2001, Stroke.

[26]  H. Sackeim,et al.  The definition and meaning of treatment-resistant depression. , 2001, The Journal of clinical psychiatry.

[27]  J. Krystal,et al.  Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. , 2000, Archives of general psychiatry.

[28]  John H Krystal,et al.  Antidepressant effects of ketamine in depressed patients , 2000, Biological Psychiatry.

[29]  D DeBrota,et al.  The responsiveness of the Hamilton Depression Rating Scale. , 2000, Journal of psychiatric research.

[30]  G. Mealing,et al.  Differences in degree of trapping of low-affinity uncompetitive N-methyl-D-aspartic acid receptor antagonists with similar kinetics of block. , 1999, The Journal of pharmacology and experimental therapeutics.

[31]  S. Southwick,et al.  Measurement of Dissociative States with the Clinician-Administered Dissociative States Scale (CADSS) , 1998, Journal of traumatic stress.

[32]  J. Peeling,et al.  Low‐Affinity NMDA Receptor Antagonists , 1997 .

[33]  D. Monaghan,et al.  NR1 and NR2 subunit contributions to N-methyl-D-aspartate receptor channel blocker pharmacology. , 1997, The Journal of pharmacology and experimental therapeutics.

[34]  J. Peeling,et al.  Low-affinity NMDA receptor antagonists. The neuroprotective potential of ARL 15896AR. , 1997, Annals of the New York Academy of Sciences.

[35]  R. Duman,et al.  Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[36]  C. Parsons,et al.  Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo , 1995, Neuropharmacology.

[37]  J. Krystal,et al.  Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. , 1994, Archives of general psychiatry.

[38]  P Bech,et al.  The Hamilton Depression Scale , 1981, Acta psychiatrica Scandinavica.

[39]  A. Beck,et al.  Assessment of suicidal intention: the Scale for Suicide Ideation. , 1979, Journal of consulting and clinical psychology.

[40]  R. C. Young,et al.  A Rating Scale for Mania: Reliability, Validity and Sensitivity , 1978, British Journal of Psychiatry.

[41]  P. Bech,et al.  QUANTITATIVE RATING OF DEPRESSIVE STATES , 1975, Acta psychiatrica Scandinavica.

[42]  A. Beck,et al.  Assessment of depression: the depression inventory. , 1974, Modern problems of pharmacopsychiatry.

[43]  R. Aitken.  Measurement of feelings using visual analogue scales. , 1969, Proceedings of the Royal Society of Medicine.

[44]  J. Overall,et al.  The Brief Psychiatric Rating Scale , 1962 .

[45]  M. Hamilton.  A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.

[46]  M. Hamilton.  The assessment of anxiety states by rating. , 1959, The British journal of medical psychology.